Pfizer Inc announced results from two phase-1 safety studies, one of PF-04360365, a humanized anti-amyloid monoclonal antibody (mAb), and another of dimebon (latrepirdine) in combination with
donepezil HCl tablets, in patients with Alzheimer's disease. ...
[PharmaBiz - 07/17/2009]